CA2509632A1 - Me-5, me-2, and epp2: human protein antigens reactive with autoantibodies present in the serum of woman suffering from endometriosis - Google Patents

Me-5, me-2, and epp2: human protein antigens reactive with autoantibodies present in the serum of woman suffering from endometriosis Download PDF

Info

Publication number
CA2509632A1
CA2509632A1 CA002509632A CA2509632A CA2509632A1 CA 2509632 A1 CA2509632 A1 CA 2509632A1 CA 002509632 A CA002509632 A CA 002509632A CA 2509632 A CA2509632 A CA 2509632A CA 2509632 A1 CA2509632 A1 CA 2509632A1
Authority
CA
Canada
Prior art keywords
seq
endometriosis
polypeptide
epp2
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002509632A
Other languages
English (en)
French (fr)
Inventor
A. Said El Shami
Bruce A. Campbell
Dennis Sustarsic
Niver P. Sahakian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics Inc
Original Assignee
Diagnostic Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diagnostic Products Corp filed Critical Diagnostic Products Corp
Publication of CA2509632A1 publication Critical patent/CA2509632A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/364—Endometriosis, i.e. non-malignant disorder in which functioning endometrial tissue is present outside the uterine cavity
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/811—Drug, bio-affecting and body treating compositions involving sex selection or contraception
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/85—Reproductive organs or embryos
    • Y10S530/852—Sperm
    • Y10S530/853—Ovary; eggs; embryos
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Biotechnology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
CA002509632A 2004-07-07 2005-07-05 Me-5, me-2, and epp2: human protein antigens reactive with autoantibodies present in the serum of woman suffering from endometriosis Abandoned CA2509632A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/887,540 2004-07-07
US10/887,540 US20060008876A1 (en) 2004-07-07 2004-07-07 ME-5, ME-2, and EPP2: human protein antigens reactive with autoantibodies present in the serum of women suffering from endometriosis

Publications (1)

Publication Number Publication Date
CA2509632A1 true CA2509632A1 (en) 2006-01-07

Family

ID=35124497

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002509632A Abandoned CA2509632A1 (en) 2004-07-07 2005-07-05 Me-5, me-2, and epp2: human protein antigens reactive with autoantibodies present in the serum of woman suffering from endometriosis

Country Status (9)

Country Link
US (7) US20060008876A1 (enExample)
EP (1) EP1614692B1 (enExample)
JP (1) JP2006051019A (enExample)
AT (1) ATE433462T1 (enExample)
AU (1) AU2005202925A1 (enExample)
CA (1) CA2509632A1 (enExample)
DE (1) DE602005014828D1 (enExample)
ES (1) ES2326324T3 (enExample)
NZ (1) NZ541063A (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8329399B2 (en) * 2006-10-27 2012-12-11 Siu K W Michael Endometrial biomarkers
US8279789B2 (en) * 2008-06-10 2012-10-02 Qualcomm Incorporated Intelligent setting of hysteresis activation timer to enter hysteresis sooner and save battery
WO2011085213A2 (en) * 2010-01-07 2011-07-14 Sanford-Burnham Medical Research Institute Pathologically-activated therapeutics
DE102012002929A1 (de) 2012-02-14 2013-08-14 Jürgen Lewald Minimalinvasives Verfahren für die Diagnose und die Therapieverlaufskontrolle der Endometriose
GB202310300D0 (en) 2023-07-05 2023-08-16 Univ Edinburgh Endometrosis markers and methods of diagnosing nedometriosis

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US652187A (en) * 1899-11-02 1900-06-19 Sigvald Krohn System of electrical distribution.
US4489166A (en) * 1982-05-27 1984-12-18 Research Corporation Monitoring of human endometrial function by radioimmunoassay of PEP
AU5068090A (en) 1989-03-07 1990-09-13 Adeza Biomedical Corporation Endometriosis diagnosis methods and reagents
US5302738A (en) 1991-03-15 1994-04-12 Hoffmann-La Roche Inc. Chiral phosphines
CA2062675A1 (en) 1991-04-09 1992-10-10 Sandra S. Fenton Endometrial antigen, composition, test kit and method for endometrial antibody determination
WO1994028021A1 (en) * 1993-05-28 1994-12-08 Medical University Of South Carolina Endometrial proteins, antigenic compositions and methods for detecting endometriosis
US5877284A (en) * 1993-08-12 1999-03-02 The Trustees Of The University Of Pennsylvania Isolated chemotactic factor from patients with endometriosis
US7122322B2 (en) * 1994-10-25 2006-10-17 The Curators Of The University Of Missouri Endometriosis-specific secretory protein
US6531277B2 (en) * 1994-10-25 2003-03-11 The Curators Of The University Of Missouri Endometriosis-specific secretory protein
US5843673A (en) * 1994-10-25 1998-12-01 Curators Of The University Of Missouri Method of screening for endometriosis
US5618680A (en) * 1994-12-28 1997-04-08 Institut De Medecine De La Reproduction De Montreal Use of ligands specific to major histocompatibility complex-class I antigens for diagnosing endometriosis
US6376201B2 (en) * 1994-12-28 2002-04-23 Procrea Biosciences Inc. Use of ligands specific to major histocompatibility complex-class I antigens for diagnosing endometriosis
WO1997035016A1 (en) 1996-03-18 1997-09-25 Novo Nordisk Biotech Inc Polypeptides having phytase activity and nucleic acids encoding same
WO1997035018A1 (en) 1996-03-21 1997-09-25 New York University Growth factor inducible serine/threonine phosphatase fin13
US6294662B1 (en) * 1996-08-27 2001-09-25 University Of South Florida Nucleic acids encoding an endometrial bleeding associated factor (ebaf)
WO1999004265A2 (en) 1997-07-17 1999-01-28 Ludwig Institute For Cancer Research Cancer associated nucleic acids and polypeptides
US6165767A (en) * 1998-03-20 2000-12-26 Incyte Pharmaceuticals, Inc. Protein phosphatase-related molecules
AU760613B2 (en) 1998-06-04 2003-05-22 Reprogen, Inc. Use of prothymosin in the diagnosis and treatment of endometriosis
AU765750B2 (en) * 1998-06-04 2003-09-25 Reprogen, Inc. Use of cathepsin s in the diagnosis and treatment of endometriosis
US6525187B1 (en) * 1998-07-31 2003-02-25 Diagnostic Products Corporation Polynucleotide encoding autoantigens associated with endometriosis
ATE374370T1 (de) 1999-01-25 2007-10-15 Siemens Medical Solutions Diag Verfahren zur diagnose von endometriose
WO2000059547A2 (en) * 1999-04-02 2000-10-12 Center For Molecular Medicine And Immunology Method of detecting endometriosis
WO2000063675A1 (en) 1999-04-16 2000-10-26 Bioincept, Inc. Identification of a serum marker for endometriosis
WO2000075321A2 (en) * 1999-06-03 2000-12-14 Curagen Corporation Polynucleotides and membrane-bound polypeptide encoded thereby
EP1238104A2 (en) 1999-11-03 2002-09-11 Metris Therapeutics Limited Agents implicated in endometriosis
GB0004232D0 (en) 2000-02-24 2000-04-12 Zeneca Ltd Diagnostic method
ES2336817T3 (es) * 2000-02-25 2010-04-16 Siemens Healthcare Diagnostics Inc. Marcadores relacionados con la endometriosis y usos de los mismos.
JP2003532078A (ja) * 2000-04-19 2003-10-28 リサーチ コーポレイション テクノロジーズ，インコーポレイテッド 子宮内膜症の診断アッセイ
WO2001079846A2 (en) * 2000-04-19 2001-10-25 Research Corporation Technologies, Inc. Diagnostic assay for endometriosis
DE10048633A1 (de) 2000-09-25 2002-04-18 Schering Ag Methode zur in vitro Diagnostik von Endometriose
US6780594B2 (en) * 2000-09-25 2004-08-24 Schering Aktiengesellschaft Method for in vitro diagnosis of endometriosis
WO2002068579A2 (en) 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
AU2002320630A1 (en) * 2001-07-17 2003-03-03 University Of Florida Detecting and treating reproductive tract disorders
AU2003295328A1 (en) * 2002-10-02 2004-04-23 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2004087874A2 (en) 2003-03-28 2004-10-14 Nuvelo, Inc. Novel nucleic acids and polypeptides
WO2005019258A2 (en) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US6843673B1 (en) * 2004-04-30 2005-01-18 Speed Tech Corp. Coaxial connector structure

Also Published As

Publication number Publication date
US20060008876A1 (en) 2006-01-12
US20100062453A1 (en) 2010-03-11
US8030007B2 (en) 2011-10-04
AU2005202925A1 (en) 2006-02-02
EP1614692A2 (en) 2006-01-11
US20070141600A1 (en) 2007-06-21
US7879562B2 (en) 2011-02-01
ES2326324T3 (es) 2009-10-07
EP1614692A3 (en) 2006-04-05
NZ541063A (en) 2008-07-31
US20080153106A1 (en) 2008-06-26
ATE433462T1 (de) 2009-06-15
US20070178528A1 (en) 2007-08-02
DE602005014828D1 (de) 2009-07-23
US20110201129A1 (en) 2011-08-18
US7981626B2 (en) 2011-07-19
US20100330696A1 (en) 2010-12-30
EP1614692B1 (en) 2009-06-10
JP2006051019A (ja) 2006-02-23

Similar Documents

Publication Publication Date Title
AU698823B2 (en) DNA sequence and encoded mammary-specific breast cancer protein
Duncan et al. Proteomics of semen and its constituents
EP0461177A1 (en) Human intra-acrosomal sperm antigen for use in a contraceptive vaccine
US8030007B2 (en) Method for the detection of endometriosis using an ME-2 antigen
US6417336B1 (en) Antibody against cleavage product or vimentin
KR0174528B1 (ko) 암과 관련된 헵토글로빈
WO1994028021A1 (en) Endometrial proteins, antigenic compositions and methods for detecting endometriosis
JP3220451B2 (ja) ブタクサからのアレルゲン蛋白質およびそれらの使用
Fliger et al. Identification of a target antigen in human anti-tubular basement membrane nephritis
EP0931262A1 (en) Biochemical markers of the human endometrium
WO2002077243A1 (en) Diagnosis of cancer or benign tumour using the aberrant expression product of the klk4 gene
JP2002504330A (ja) 組換え型活性ヒト透明帯タンパク質３（ｈＺＰ３）
US5773215A (en) Tumor marker protein for cancer risk assessment
US5858685A (en) Prostate specific antigen from benign prostatic hyperplasia and its use in diagnosis
JP2002516658A (ja) 胎盤タンパク質１３
US6531277B2 (en) Endometriosis-specific secretory protein
JPWO2002042769A1 (ja) 抗ラミニン−１抗体の測定法およびその応用
JP2648952B2 (ja) 種々の病理的状態に於いてｐｓ２遺伝子から特異的に発現される蛋白質及びその断片、該蛋白質及び／又はその断片から得られる抗体、並びに病理的状態に対する検出、診断及び治療への該蛋白質、その断片及び抗体の適用
JP3455782B2 (ja) 強皮症の診断薬
JP5311117B2 (ja) 免疫細胞刺激活性を有する機能ペプチド
Laurie et al. Immunological and partial sequence identity of mouse BM180 with wheat α-gliadin
Szabó Pregnancy-Related Protein Concentrations During Normal Pregnancy
WO2004095033A2 (en) Compositions and methods for accurate early pregnancy diagnosis in ungulates
Lauriel et al. Substrates and antibodies: Unfractionated gliadin was purchased from Fluka (Ronkonkoma NY). BMS was prepared by EDTA extraction of EHS tumor matrix (3). Preparation of rat anti
Ruoslahti Markku Seppala

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued